Policy & Politics
FDA Approves Boehringer Ingelheim's Protease Inhibitor Aptivus to Treat Drug-Resistant HIV
June 23, 2005
FDA on Wednesday approved Boehringer Ingelheim's protease inhibitor Aptivus to be used in combination with Abbott Laboratories' Norvir for HIV/AIDS patients who have become resistant to other drugs, Reuters reports. Boehringer on Wednesday said Aptivus -- known generically as tipranavir -- will be available at pharmacies nationwide within two weeks (Reuters, 6/23). Protease inhibitors work by blocking the action of an enzyme that cuts HIV proteins into the shorter sections that the virus needs to replicate (Kaiser Daily HIV/AIDS Report, 5/4). Although FDA has approved eight other protease inhibitors, most HIV/AIDS patients develop resistance to the drugs at some time. Boehringer said it hopes to gain approval of Aptivus from E.U. regulators by the end of this year, according to Andres Barner, the company's head of research (Reuters, 6/23).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.